Journals / MN Kardiyoloji / 2005 / Cilt: 12 - Sayı: 2

Metabolic syndrome: Importance and treatment

Metabolik sendrom: Önemi ve tedavisi

Pages
133–138
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the pathophysiology of the MS is summarized and effects of both the components and the treatment options of MS on coronary heart disease are reviewed with reference to clinical trials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Metabolic syndrome (MS) is a public health problem which is becoming increasingly common worldwide.
📊
Key Findings & Data:Each factor is associated with increased risk for coronary heart disease (CHD).
💡
Conclusion & Impact:In this review, the pathophysiology of the MS is summarized and effects of both the components and the treatment options of MS on coronary heart disease are reviewed with reference to clinical trials.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Metabolik sendrom X · Koroner hastalık · Metabolic Syndrome X

Abstract

Metabolic syndrome (MS) is a public health problem which is becoming increasingly common worldwide. Factors characteristic of the MS are abdominal obesity, atherogenic dyslipidemia, high blood pressure and insulin resistance. Each factor is associated with increased risk for coronary heart disease (CHD). MS was defined in conformity with that proposed in the NCEP ATP III guidelines, namely in the presence of 3 out of 5 relevant components. This syndrome was identified in Turkish population in 31% of men and 43% of women with a total of 9.2 million adults. MS existed in 3 out of each 8 adults and 1 out of 6 adults have high risk for CHD. According to TEKHARF study, metabolic syndrome was present in 53% of patients with established CHD so metabolic syndrome is an important public health problem in Turkish people. In this review, the pathophysiology of the MS is summarized and effects of both the components and the treatment options of MS on coronary heart disease are reviewed with reference to clinical trials.

Özet

Her biri koroner kalp hastalığı (KKH) riskini artıran abdominal obezite, aterojenik dislipidemi, artmış kan basıncı ve insülin direncinden meydana gelen metabolik sendrom (MS), tüm dünyada giderek artan bir halk sağlığı sorunudur. NCEP kılavuzunun ATP III revizyonuna uygun bir şekilde beş unsurdan üçünün varlığı ile tanı konan MS, toplumumuzda 30 yaş üzerindeki erkek bireylerin %31'inde ve kadın bireylerin %43'ünde olmak üzere toplam 9.2 milyon erişkinimizde mevcuttur. Her 8 erişkinimizin 3'ünde MS var olup, her 6 erişkinimizin 1'i KKH için yüksek riske sahiptir. TEKHARF çalışması veritabanına göre KKH gelişiminin %53'ünden sorumlu tutulan MS, Türk toplumu için de oldukça önemli bir problemdir. Bu derlemede MS fizyopatolojisine kısaca değinilmiş, MS unsurlarının ve tedavi seçeneklerinin koroner kalp hastalığına olan etkileri klinik çalışmalar ışığında gözden geçirilmiştir.

🔖

Cite This Article

ÇAKMAK, N., ÇAM, N. (2005). Metabolic syndrome: Importance and treatment. MN Kardiyoloji, Cilt: 12 - Sayı: 2, 133–138. https://ajindex.com/articles/297584

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97
  2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diab Care 2001; 24:683-9
  3. Onat A, Sansoy V. Halkımızda koroner hastalığın başsuçlusu;abolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve sek risk kriterleri. Türk Kardiyol Dern Arş 2002; 30:8-15
  4. Milani V. R, Lavie J. C. Prevalance and profile of metabolic drome in patients following acute coronary events and îcts of therapeutic lifestyle change with cardiac rehabilitation. J Cardiol 2003; 92:50-4
  5. Tchemof A, Lamarche B, Prud'Home D, et al. The dense L phenotype: association with plasma lipoprotein levels, eral obesity and hyperinsulinemia in men. Diabetes Care 36; 19:629-37
  6. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and. ■diovascular disease. J Clin Endocrinol Metab 2001; 86:713-18
  7. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose pression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993; 259:87-91
  8. Steppan CM, Bailey ST, Bhat S, et al. The hormon resistin ks obesity to diabetes. Nature 2001; 409:307-12
  9. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage Dduct of 30-kDa adipocyte complement-related protein creases fatty acid oxidation in muscle and causes weight loss mice. Proc Natl Acad Sci USA 2001; 98:2005-10. 10.Esposito K, Nicoletti G, Giagliano D. Obesity, cytokines and idothelial dysfunction. J Endocrinol Invest 2002; 25:646-9. 11.Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive otein in healthy subjects: associations with obesity, insulin sistance and endothelial dysfunction: a potential role for rtokines originating from adipose tissue? Arterioscler Thromb ascBioM999; 19:972-8. 12.Ouchi N, Kihara S, Funahashi T, et al. Reciprocal ssociation of CRP with adiponectin in blood stream and dipose tissue. Circulation 2003; 107:671-4. 13.Fröhlich M, Imhof A, Berg G, et al. Association between C-jactive protein and features of the metabolic syndrome,liabetes Care 2000; 23:1835-9. 14.Rao SV, Donahue M, Pi-Sunyer X, Fuster V. Obesity as a risk actor in coronary artery disease. Am Heart J 2001; 142:1102-7. 15.Hokanson JE, Austin MA. Plasma/triglyceride level is a risk actor for cardiovascular disease